<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580190</url>
  </required_header>
  <id_info>
    <org_study_id>A8821006</org_study_id>
    <nct_id>NCT00580190</nct_id>
  </id_info>
  <brief_title>Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects</brief_title>
  <official_title>A Phase I, Randomized, Placebo Controlled, Parallel Group, Single Dose Study To Evaluate The Effects Of PF-00572778 And Alprazolam On A Naloxone Challenge In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PF-00572778, a CRH antagonist, is expected to attenuate adrenocorticotropin (ACTH) and
      cortisol responses to naloxone by blocking the effect of the CRH increases induced by
      naloxone at the postsynaptic receptors. Demonstration of a statistically significant
      attenuation of naloxone induced increases in cortisol and/or ACTH concentrations by
      PF-00572778 compared to placebo would thus constitute proof of mechanism for the compound.
      Therefore, this study is to evaluate pharmacodynamic effects of PF-00572778 following
      naloxone challenge in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Date of termination was Feb. 7, 2008. Reasons of termination were due to elevation of liver
    function tests and long elimination half-life of the compound.
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the cortisol concentration time curve from 0 to 3 hours ( AUC(0-3) ) following naloxone challenge</measure>
    <time_frame>1st day on treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>1st day on treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach the maximum observed serum concentration (Tmax)</measure>
    <time_frame>1st day on treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory tests, vital signs, ECGs, adverse events monitoring, and physical&lt;br&gt;examinations</measure>
    <time_frame>34 days (weekly)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak concentrations for plasma cortisol and ACTH</measure>
    <time_frame>1st day on treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time = 0 to time of the last quantifiable serum PF-00572778 concentration (AUClast)</measure>
    <time_frame>2nd day on treatment (Days 6-7)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the ACTH concentration curve from 0 to 3 hours ( AUC(0-3) ) following naloxone challenge</measure>
    <time_frame>1st day on treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam</intervention_name>
    <description>tablet, 0.5 mg, single dose, only on Day 7 of the study</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00572778</intervention_name>
    <description>solution, 500 mg, single dose, only on Day 7 of the study</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male and/or female subjects between the ages of 18 and 45 years; Body Mass Index
        (BMI) of approximately 18 to 30 kg/m2; and a total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

        Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
        gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease;
        Family (1st degree relatives) and personal history of meeting Diagnostic and Statistical
        Manual -IV (DSM-IV) criteria for alcohol abuse or dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8821006&amp;StudyName=Evaluation%20Of%20PF-00572778%20And%20Alprazolam%20On%20Naloxone%20Challenge%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <last_update_submitted>September 11, 2009</last_update_submitted>
  <last_update_submitted_qc>September 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

